Kwanan nan, Jaridar British Journal of Clinical Pharmacology ta buga jagorar asibiti ta farko da Cibiyar Ingantaccen Kimiyya da Innovation ta Burtaniya (CERSI PGx) ta haɓaka, mai taken "Gwajin nau'in halittar CYP2C19 don clopidogrel: Jagorar da Cibiyar Ingantaccen Kimiyya da Innovation ta Burtaniya ta haɓaka don kimiyyar tsara dokoki da kirkire-kirkire a cikin pharmacogenomics (CERSI PGx)". Wannan takardar ta mayar da hankali kan ƙimar asibiti na CYP2C19 genotyping a cikin jagorancin maganin clopidogrel.
Game da CERSI PGx
CERSI PGx yana ɗaya daga cikin cibiyoyin kimiyya da kirkire-kirkire guda bakwai da gwamnatin Burtaniya ke tallafawa waɗanda aka ƙaddamar a watan Janairun 2025. Jami'ar Liverpool ce ke jagorantar shirin, kuma Innovate UK, Majalisar Binciken Lafiya (MRC), Hukumar Kula da Magunguna da Kayayyakin Kiwon Lafiya (MHRA), da Ofishin Kimiyyar Rayuwa (OLS) ne ke ba da kuɗin haɗin gwiwa. Cibiyar tana da nufin hanzarta haɗakar magunguna (PGx) cikin aminci da inganci ta Hukumar Lafiya ta Ƙasa (NHS) ta hanyar magance manyan shingayen aiwatarwa. Wannan jagorar ita ce jagorar asibiti ta farko da aka bayar tun lokacin da aka kafa CERSI PGx.
Me yasa CYP2C19 ke da mahimmanci ga Clopidogrel?
CYP2C19 muhimmin memba ne na dangin enzyme na cytochrome P450, wanda ke da alhakin kunna metabolism ko rashin kunna magunguna da yawa. Bambancin kwayoyin halitta a cikin CYP2C19 yana haifar da bambance-bambance masu mahimmanci tsakanin mutane a cikin metabolism na magunguna, yana shafar inganci da aminci.
Clopidogrel magani ne da ake amfani da shi sosai wajen hana thrombosis a cikin cututtukan jijiyoyin zuciya, bugun jini na ischaemic, cututtukan jijiyoyin gefe, da kuma fibrillation na atrial. A matsayin prodrug, clopidogrel yana buƙatar kunna metabolism ta hanyar CYP2C19. Jagorar ta rarraba mutane zuwa ga ultrarapid, sauri, al'ada, matsakaici, da kuma rashin metabolism bisa ga nau'in CYP2C19. Masu ɗauke da asarar alleles masu aiki (misali, CYP2C192 da *3*) - masu metabolizers na matsakaici da marasa kyau - ba za su iya kunna clopidogrel yadda ya kamata ba, wanda ke haifar da rashin isasshen hana platelet da kuma ƙaruwar haɗarin sake dawowar thrombosis.
Yawan kwayar halittar CYP2C192 yana da kusan kashi 15% a Turai, kashi 30% a Kudancin Asiya, kuma yana da kusan kashi 60% a cikin al'ummar 'yan asalin Tekun.
Babban Shawara: Gwajin CYP2C19 na Duniya don Clopidogrel
Jagororin ya bayyana cewa, ba tare da la'akari da alamar ba, duk marasa lafiyar da ake la'akari da clopidogrel ya kamata a yi musu magani.CYP2C19Tsarin halittar jini.Dangane da sakamakon, ya kamata a tsara maganin antiplatelet:
-Rashin ingantaccen metabolismYa kamata a guji clopidogrel kuma a yi amfani da wasu magunguna waɗanda ba su dogara da metabolism na CYP2C19 ba, kamar ticagrelor ko prasugrel.
-Matsakaici masu narkewar abinciYa kamata kuma a yi la'akari da wasu magunguna ko hanyoyin da aka gyara maimakon kawai ƙara yawan clopidogrel.
A Burtaniya, an amince da amfani da clopidogrel don rigakafin atherothrombotic na biyu, don matsakaicin zuwa babban haɗarin harin ischemic na wucin gadi (TIA) ko bugun jini mai sauƙi, da kuma don hana atherothrombotic da thromboembolic abubuwan da ke faruwa a cikin atrial fibrillation.
Bayan Clopidogrel: Sauran Magunguna Inda Tsarin Halittar CYP2C19 Yake da Muhimmanci
Darajar CYP2C19 genotyping ta wuce clopidogrel. A matsayin babban enzyme mai narkewar magunguna, CYP2C19 kuma yana taka muhimmiyar rawa a cikin metabolism na voriconazole, magungunan rage damuwa da yawa, da kuma masu hana proton pump (PPIs). Jagorori da yawa na ƙasashen duniya da na ƙasa sun ba da shawarar yin amfani da genotype da aka tsara don waɗannan magunguna.
1. Magungunan rage damuwa (SSRIs)
Magungunan da ke hana sake amfani da serotonin (SSRIs) - kamar su sertraline, citalopram, da escitalopram - su ne magunguna na farko da ke haifar da ɓacin rai kuma galibi ana sarrafa su ta hanyar CYP2C19. Ayyukan enzyme na CYP2C19 kai tsaye suna ƙayyade yawan waɗannan magungunan a cikin jini. Marasa ƙarfi suna da raguwar kawar da magunguna da kashi 30%-60%, wanda ke sa su ga mummunan sakamako kamar tsawaita tazara ta QT da kuma kwantar da hankali. Magungunan da ke rage yawan sinadarin serotonin sau da yawa suna da yawan sinadarin plasma da ba a iya warkewa ba, wanda ke haifar da jinkirin amsawar magani da kuma ƙaruwar haɗarin daina shan magani.
Jagorar 2023 ta Clinical Pharmacogenetics Implementation Consortium (CPIC) ta bayyana cewa rashin ingantaccen metabolism na masu shan citalopram ko escitalopram yana da babban haɗarin tsawaita QT kuma yana ba da shawarar rage kashi 50%. Jagorar 2021 ta Dutch Pharmacogenetics Working Group (DPWG) ta ba da shawara cewa marasa ingantaccen metabolism ya kamata su sami matsakaicin adadin escitalopram da aka rage da kashi 50%, kuma cewa masu ƙarancin metabolizer na ultrapid ya kamata su guji escitalopram gaba ɗaya. Ga sertraline, DPWG ya ba da shawarar shan kowace rana ba fiye da 75 MG ba a cikin marasa ingantaccen metabolism.
Abu mai mahimmanci, yarjejeniyar ƙwararrun masana kimiyyar Sin da aka buga kwanan nan kan gwajin magunguna a fannin tabin hankali (2025) - wanda ƙungiyar haɗin gwiwar magunguna ta Precision Medicine Collaboration Group ta ƙungiyar tabin hankali ta ƙasar Sin ta ƙirƙiro - ta ƙunshi shawarwari a sarari don yin gwajin kwayoyin halitta na CYP2C19. Bayanin yarjejeniya ya lura cewa shawarwarin daidaita allurai daga jagororin ƙasa da ƙasa kamar CPIC da DPWG don enzymes masu narkewar magunguna (gami da CYP2C19) za a iya ambaton su ga al'ummar Sinawa. Saboda haka, yin gwajin kwayoyin halitta na CYP2C19 kafin fara maganin SSRI (misali, escitalopram) yana ba da damar inganta allurai ko canzawa zuwa wasu magunguna waɗanda CYP2C19 ba ta narkewa ba, ta haka ne ake cimma daidaiton magani, inganta yawan amsawa, da kuma rage abubuwan da ba su dace ba.
2. Masu hana famfon Proton (PPIs)
Ana amfani da magungunan hana shan sinadarin proton pump - ciki har da omeprazole, lansoprazole, da pantoprazole - sosai don magance matsalolin da suka shafi acid kamar cututtukan gastroesophageal reflux da peptic ulcers. Tsarin aikinsu kuma ya dogara sosai akan CYP2C19. Marasa lafiya da ke da nau'ikan kwayoyin halittar CYP2C19 daban-daban suna nuna bambanci mai yawa dangane da PPIs. Masu ɗauke da asarar alleles masu aiki (*2, *3) sun ƙara yawan shan magani, wanda zai iya ƙara rage shan sinadarin acid amma kuma yana ƙara haɗarin mummunan sakamako. Sabanin haka, masu daidaita metabolism na yau da kullun suna da ƙarancin yawan sinadarin plasma kuma suna iya fuskantar raunin rage shan sinadarin acid, kodayake bambancin da ke tsakanin mutane ya kasance mai yawa.
Jagorar CPIC ta 2020 ga PPIs ta ba da shawara cewa masu rage yawan sinadarin omeprazole ko makamantansu suna rage yawan sinadarin da sauri, wanda hakan ke haifar da rashin isasshen yawan sinadarin a cikin jini da kuma rashin rage yawan sinadarin acid. A cikin waɗannan marasa lafiya, ya kamata a ƙara yawan sinadarin kuma a sa ido kan martanin warkewa. Ga marasa lafiya marasa isasshen sinadarin metabolism, rage yawan sinadarin yana da jinkiri kuma yawan sinadarin plasma na iya ƙaruwa; yayin da inganci na iya zama mafi kyau, yuwuwar gubar magani yana ƙaruwa. Rage yawan magani da kuma sa ido kan martani abu ne mai ma'ana. Saboda haka, ga marasa lafiya da ke fara maganin PPI ko waɗanda ke fuskantar mummunan martani ko mummunan sakamako, ana ba da shawarar yin amfani da CYP2C19 genotyping don jagorantar allurar da aka keɓance, inganta inganci, da kuma rage abubuwan da ba su dace ba.
3. Voriconazole
Voriconazole wani maganin kashe ƙwayoyin cuta ne mai faɗi wanda ake amfani da shi don magance manyan cututtukan fungal kamar aspergillosis mai yaɗuwa. Yana da ƙaramin taga na magani: yawan sinadarin plasma mai yawa yana ƙara haɗarin gubar hanta da matsalolin gani, yayin da ƙarancin sinadarin ke haifar da gazawar magani. Ci gaban metabolism na voriconazole galibi yana faruwa ne ta hanyar CYP2C19, kuma bambancin kwayoyin halitta yana da tasiri sosai akan yawan sinadarin plasma.
CPIC ta buga wata ka'ida ta musamman kan CYP2C19 da voriconazole a shekarar 2016. Ta bayyana cewa magungunan rage yawan sinadarin voriconazole sun rage yawan sinadarin voriconazole a cikin jini kuma sau da yawa ba sa kai ga matakan warkewa da aka tsara. Magungunan rage yawan sinadarin metabolism suna da yawan sinadarin da ke cikin jini da kuma karuwar haɗarin mummunan sakamako. Ka'idar CPIC ta ba da takamaiman shawarwari kan yadda za a yi amfani da shi bisa ga nau'in kwayar halitta. Misali, magungunan rage yawan sinadarin ultrapid na manya ya kamata su sami wasu magunguna na farko waɗanda ba su dogara da tsarin CYP2C19 ba, kamar isavuconazole, liposomal amphotericin B, ko posaconazole. Saboda haka, yin amfani da kwayoyin halitta na CYP2C19 kafin maganin voriconazole yana ba da damar yin allurar da aka keɓance kuma yana rage yawan abubuwan da suka faru da suka shafi magani.
Muhimmancin Asibiti: Yin Maganin da Ya Fi Inganci
Sabuwar jagorar da aka fitar ta sake sanya tsarin halittar CYP2C19 a sahun gaba a fannin maganin daidaito. Duk da haka, yana da mahimmanci a fahimci cewa amfani da tsarin halittar CYP2C19 a asibiti ya wuce clopidogrel - daga voriconazole (antifungal) da SSRIs (antidepressants) zuwa masu hana proton pump don rage acid. Tsarin halittar CYP2C19 yana aiki azaman "kamfas" don maganin magunguna.
Yayin da maganin daidaito ke samun karɓuwa sosai, ƙarin jagororin da suka dace suna haɗa tsarin halittar CYP2C19 cikin ayyukan magunguna na yau da kullun. Ga marasa lafiya, sanin nau'in halittar CYP2C19 nasu yana taimaka musu fahimtar bayanin martabar maganinsu na mutum ɗaya kuma yana ba da damar yanke shawara tare da likitansu don ƙirƙirar tsarin magani mafi dacewa. Ga likitoci, haɗa sakamakon gwajin kwayoyin halitta na gaskiya cikin yanke shawara na rubuta magani hanya ce mai ƙarfi don inganta ingancin magani da tabbatar da amincin marasa lafiya.
Gwajin Macro & Micro'sMaganin Tsarin Halittar CYP2C19
Gwajin Macro & Micro yana ba da kayan aikin tantance kwayoyin halitta na CYP2C19 bisa ingantaccen tsarin maye gurbi mai hana ƙaruwa (ARMS) tare da binciken Taqman tare da fasaloli masu zuwa:
-Cikakken ɗaukar nauyin allele- ganoCYP2C192, *3, da *17ba tare da rasa bambance-bambancen maɓalli ba.
-Ingantaccen iko na inganci- ya haɗa da na'urorin sarrafawa marasa kyau/masu kyau, na'urar sarrafawa ta ciki, da kuma enzyme na UDG don kula da inganci na matakai huɗu don tabbatar da sakamako mai kyau.
-Cirewa ta atomatik- mai jituwa da na'urar fitar da sinadarin nucleic acid mai sarrafa kansa ta Macro & Micro-Test, wanda ke inganta yadda ake gudanar da aiki.
-Dacewar da ta dace- yana aiki tare da kayan aikin PCR na yau da kullun a kasuwa, gami da ABI 7500 Hongshi SLAN 96P.
-Fassarar sakamako ta atomatik– software na nazari na musamman (akan ABI 7500, SLAN 96P, da sauransu) yana ba da damar fassara sakamako ta atomatik, yana haɓaka inganci.
-POCT shirye-shiryen atomatik– HWTS AIO800 Cikakken Mai Aiki da Nucleic Acid Amplification Analyzer yana ba da damar aiki "samfurin shiga, fitar da sakamako".
Tare da ci gaba da ci gaban magunguna, ana sa ran tsarin halittar CYP2C19 zai amfanar da yawan marasa lafiya, yana mai da hankali kan magungunan da suka dace daga ra'ayi zuwa ayyukan asibiti na yau da kullun. Sabuwar jagorar CERSI PGx da aka buga tana ƙarfafa muhimmiyar rawar da gwajin CYP2C19 ke takawa ba wai kawai ga clopidogrel ba har ma da jerin magunguna masu tasowa, gami da magungunan rage radadi, masu hana proton pump, da voriconazole. Don sauƙaƙe ɗaukar magungunan da aka tsara bisa ga genotype, hanyoyin gwaji masu inganci da masu amfani suna da mahimmanci. Fayil ɗin gwajin magunguna na Macro & Micro-Test, wanda ke ɗauke da cikakken ɗaukar hoto na allele, ingantaccen sarrafa inganci, da dandamalin da aka shirya don sarrafa kansa, yana da nufin tallafawa masu samar da kiwon lafiya wajen aiwatar da maganin daidai da kuma kare lafiyar marasa lafiya.
Kayayyaki Masu Alaƙa:
Nassoshi:
1. Lima JJ, Thomas CD, Barbarino J, da sauransu. Jagorar Cibiyar Nazarin Magungunan ...
2.Lee CR, Luzum JA, Sangkuhl K, da sauransu. Jagorar Haɗin gwiwar Aiwatar da Magungunan ...
3. Cibiyar Kula da Lafiya da Ingantaccen Kulawa ta Ƙasa (NICE). Gwajin nau'in halittar CYP2C19 don jagorantar amfani da clopidogrel bayan bugun jini na ischaemic ko harin ischaemic na ɗan lokaci. Jagorar Bincike DG59. An buga: 31 Yuli 2024.
4. Ƙungiyar Haɗin gwiwar Binciken Magunguna na Precision na Ƙungiyar Ilimin Halayyar Dan Adam ta China. Ƙwararru sun amince kan gwajin magunguna a fannin ilimin hauka (2025) [Zhonghua Jing Shen Ke Za Zhi].Mujallar Nazarin Ilimin Halayyar Dan Adam ta kasar Sin. 2025;58(6):434-445. doi:10.3760/cma.j.cn11366120240611-00181
5.Dello Russo C, Frater I, Kuruvilla R, da sauransu. Gwajin nau'in halittar CYP2C19 don clopidogrel: Jagorar da Cibiyar Kyau ta Burtaniya ta ƙirƙiro don kimiyyar tsara dokoki da kirkire-kirkire a fannin magunguna (CERSI-PGx). Br J Clin Pharmacol. 2025. DOI: 10.1093/bjcp/…
6.Moriyama B, Owusu Obeng A, Barbarino J, da sauransu. Jagororin Cibiyar Nazarin Magungunan ...
7. Bousman CA, Stevenson JM, Ramsey LB, da sauransu. Jagorar Cibiyar Nazarin Magungunan ...
8.Brouwer JMJL, Nijenhuis M, Soree B, da sauransu. Jagorar Ƙungiyar Aiki ta Dutch Pharmacogenetics (DPWG) don hulɗar kwayar halitta tsakanin CYP2C19 da CYP2D6 da SSRIs. Eur J Hum Genet. 2021. doi:10.1038/s41431-021-00894-2.
Lokacin Saƙo: Afrilu-22-2026